Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto

Novartis International AG: Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto. Overall summary score was also significantly higher for Entresto patients than for patients not taking Entresto, as measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12) These improvements were reported early by Entresto patients, with a median follow-up time of 32 days 21.4 percent of patients treated with Entresto in this interim data cut reported a large improvement (>20-point difference from baseline) in the overall summary score versus 12.5 percent of patients not taking Entresto Novartis announced today new real world evidence from the CHAMP-HF registry comparing Entresto (sacubitril/valsartan) patients to patients not taking Entresto. This pre-specified analysis of an interim data cut from the CHAMP-HF registry showed that chronic heart failure (HF) patients with reduced ejection fraction (HFrEF) taking Entresto reported early, statistically significant improvement in health status, as measured by the KCCQ-12 overall summary score (KCCQ-OS). This finding was driven by statistically significant improvements in symptom frequency and quality of life domains of the KCCQ-12. The study findings were presented today by lead investigator Yevgeniy Khariton, MD, MSc, Saint Luke's Hospital, Mid-America Heart Institute, University of Missouri-Kansas City, as a part of a late-breaking session at the European Society of Cardiology Heart Failure (ESC-HF) Congress in Vienna, Austria.